Phase 2b Study of Taxol Plus Sorafenib or Placebo in Patients With Advanced Breast Cancer
NCT00499525
Unknown
RATIONALE: Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving paclitaxel together with sorafenib may kill more tumor cells. PURPOSE: This randomized phase II trial is studying how well paclitaxel works when given together with or wit... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
05/01/2019
Locations: Northwest Alabama Cancer Center, PC - Muscle Shoals, Muscle Shoals, Alabama +42 locations
Conditions: Breast Cancer
Register for Updates
Evaluation of Safety and Efficacy of Electrochemotherapy in the Treatment of Pancreatic Adenocarcinoma
NCT02514421
Completed
The purpose of this study is to see how well electrochemotherapy works at treating people with Stage III pancreatic adenocarcinoma. Electrochemotherapy is a treatment that combines electroporation and chemotherapy administration. Electroporation uses an electric current to produce holes in pancreatic tumor, which causes the tumor cells to die or take up a higher concentration of administered chemotherapy agent. This study will test the safety and look at the effect of electrochemotherapy in the... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2019
Locations: The University of Texas Health Science Center at Houston, Houston, Texas
Conditions: Pancreatic Adenocarcinoma
Register for Updates
Prospective Phase I Study of GAX for Metastatic Pancreatic Cancer
NCT02581501
Withdrawn
GAX represents a novel approach to the development of cancer chemotherapy agents in pancreatic cancer and is based upon extensive laboratory investigations for the induction of apoptosis in pancreatic carcinoma cells.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/16/2019
Locations: Stamford Hospital Bennett Cancer Center, Stamford, Connecticut
Conditions: Pancreatic Cancer
Register for Updates
T-DM1 With Abraxane and Lapatinib for Metastatic HER2 Positive Breast Cancer
NCT02073916
Completed
This open-label, single-center Phase Ib study will assess the safety and tolerability of combining trastuzumab emtansine (T-DM1) with Lapatinib and Abraxane in patients with metastatic HER2-positive breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/12/2019
Locations: Houston Methodist Hospital, Houston, Texas
Conditions: Metastatic Breast Cancer
Register for Updates
Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer
NCT00011986
Completed
Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which combination chemotherapy regimen is most effective in treating ovarian epithelial cancer and peritoneal cancer. Randomized phase III trial to compare the effectiveness of various combination chemotherapy regimens in treating patients who have stage III or stage IV ovarian cancer or primary peritoneal cancer.
Gender:
FEMALE
Ages:
All
Trial Updated:
04/03/2019
Locations: Gynecologic Oncology Group, Philadelphia, Pennsylvania
Conditions: Primary Peritoneal Carcinoma, Stage III Ovarian Cancer, Stage IV Ovarian Cancer
Register for Updates
Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas
NCT01088815
Completed
This is an open-label, single arm, multi-center, Phase II trial to evaluate the progression free survival in patients with metastatic adenocarcinoma of the pancreas treated with a hedgehog inhibitor (GDC-0449) in combination with chemotherapy (gemcitabine and nab-Paclitaxel).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/02/2019
Locations: Translational Genomics Research Institute (TGen), Scottsdale, Arizona +2 locations
Conditions: Metastatic Pancreatic Cancer
Register for Updates
Randomized Phase II Trial of Pre-Operative Gemcitabine and Nab Paclitacel With or With Out Hydroxychloroquine
NCT01978184
Completed
This is a randomized phase II trial that will examine the ability of the hydroxychloroquine to improve the clinical activity of a pre-operative regimen of gemcitabine and nab-paclitaxel in subjects with potentially resectable adenocarcinoma of the pancreas. Eligible subjects will receive 2 cycles of gemcitabine and nab-paclitaxel (day 1, 8, 15) with or without hydrocychloroquine followed by surgical resection. Primary endpoint will be histologic response as graded by Evans criteria. Secondary en... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/25/2019
Locations: Hillman Cancer Center, Pittsburgh, Pennsylvania
Conditions: Pancreatic Cancer
Register for Updates
Phase 2 Nab® -Paclitaxel (Abraxane®) Plus Gemcitabine in Subjects With Locally Advanced Pancreatic Cancer (LAPC)
NCT02301143
Completed
This clinical study is in subjects who are 18 years old or older with locally advanced pancreatic cancer who have not received prior treatment for their pancreatic cancer. The study treats all subjects with nab-Paclitaxel plus gemcitabine for approximately 6 months of treatment. Subjects who complete the treatment will choose, with their treating physicians, what additional treatment should be given: more nab-Paclitaxel plus gemcitabine, Chemoradiation therapy, or surgery to treat the locally ad... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/18/2019
Locations: Mayo Clinic - Arizona, Scottsdale, Arizona +41 locations
Conditions: Pancreatic Neoplasms
Register for Updates
Vandetanib, Carboplatin, and Paclitaxel in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer That Can Be Removed by Surgery
NCT00459121
Terminated
RATIONALE: Vandetanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving vandetanib together with chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. PURPOSE:... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
03/13/2019
Locations: Barbara Ann Karmanos Cancer Institute, Detroit, Michigan
Conditions: Lung Cancer
Register for Updates
Tipifarnib Plus Radiation Therapy After Combination Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer
NCT00025480
Completed
RATIONALE: Tipifarnib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by making tumor cells more sensitive to radiation therapy. Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells either by killing the cells or by stopping them from dividing and may also make tumor cells more sensitive to radiation therapy. PURPOSE: Th... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
03/12/2019
Locations: Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Lung Cancer
Register for Updates
Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer
NCT00807768
Unknown
This randomized phase III trial studies pelvic radiation therapy to see how well it works compared with vaginal implant radiation therapy, paclitaxel, and carboplatin in treating patients with high-risk stage I or stage II endometrial cancer. Radiation therapy uses high-energy x-rays to kill tumor cells. Implant radiation therapy uses radioactive material placed directly into or near a tumor to kill tumor cells. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different wa... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/08/2019
Locations: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama +539 locations
Conditions: Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Fatigue, Neurotoxicity Syndrome, Obesity, Stage I Uterine Corpus Cancer AJCC v7, Stage II Uterine Corpus Cancer AJCC v7
Register for Updates
Cisplatin and Radiation Therapy Followed by Paclitaxel and Carboplatin in Treating Patients With Stage IB-IVA Cervical Cancer
NCT01295502
Unknown
This phase I trial studies the side effects and the best dose of paclitaxel and carboplatin after cisplatin and radiation therapy in treating patients with stage IB-IVA cervical cancer. Drugs used in chemotherapy, such as cisplatin, paclitaxel, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving paclitaxel an... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/08/2019
Locations: UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California +13 locations
Conditions: Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Stage IB Cervical Cancer AJCC v6 and v7, Stage IIA Cervical Cancer AJCC v7, Stage IIB Cervical Cancer AJCC v6 and v7, Stage IIIA Cervical Cancer AJCC v6 and v7, Stage IIIB Cervical Cancer AJCC v6 and v7, Stage IVA Cervical Cancer AJCC v6 and v7
Register for Updates